ReviewDiagnostics (Basel, Switzerland)2024
Carbohydrate Antigen 125 (CA 125): A Novel Biomarker in Acute Heart Failure.
Review in Diagnostics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Carbohydrate antigen 125 and clinical outcomes in heart failure: systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- Carbohydrate antigen 125 (CA125) following acute myocardial infarction: effects of empagliflozin and association with heart failure readouts in the EMMY trial.Scientific reports · 2025Trial
- Serum CA125 for Detection of Antibody-Mediated Rejection in Heart Transplantation Recipients.International journal of molecular sciences · 2026Article
- Diagnostic and prognostic biomarkers in heart failure and myeloproliferative neoplasms: clinical applications and risk scores - a narrative review.Cardio-oncology (London, England) · 2026Review
- Convulsive Syncope Due to Complete Atrioventricular Block in a Remote Area: The Critical Role of Helicopter Emergency Medical Services.Life (Basel, Switzerland) · 2026Article
- From Tumor Marker to Congestion Indicator: The Expanding Role of CA-125 in Heart Failure and Beyond.Health science reports · 2026Article
- SERS-Based Immunoassay on Ag/ZnO Nanorod Substrates for Detection of CA125 Antigen.ACS measurement science au · 2026Article
- Point-of-care ultrasound: Uniting cardiology and nephrology at the bedside.World journal of cardiology · 2025Review
- Methamphetamine-Associated Cardiomyopathy and Cardioembolic Stroke: Brain-Heart-Gut Axis Crosstalk, Diagnostic Strategies, and Anticoagulation Challenges.International journal of molecular sciences · 2025Review
- Combination of the Fibrosis 4 Index and Carbohydrate Antigen 125 to Predict Morbidity and Mortality in Acute Heart Failure.Reviews in cardiovascular medicine · 2025Article
- Heart Failure Biomarkers-Pathophysiology, Diagnosis, Prognosis and Clinical Relevance.International journal of molecular sciences · 2025Review
- Integrating Novel Biomarkers into Clinical Practice: A Practical Framework for Diagnosis and Management of Cardiorenal Syndrome.Life (Basel, Switzerland) · 2025Review
- Biomarkers in Heart Failure: A Review and a Wish.International journal of molecular sciences · 2025Review
- CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations.Journal of clinical medicine · 2025Review
- Serum CA125: a prognostic biomarker for mortality in chronic heart failure.BMC cardiovascular disorders · 2025Article
- Predictive Factors of Non-Elevation of Carcinoembryonic Antigen 125 in Acute Heart Failure.Life (Basel, Switzerland) · 2025Article
- The kinetics of CA125 levels as a prognostic marker for in-hospital mortality in patients with acute heart failure: a pilot study.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure is a global major healthcare problem with millions of hospitalizations annually and with a very high mortality. There is an increased interest in finding new and reliable biomarkers for the diagnostic, prognostic and therapeutic guidance of patients hospitalized for acute heart failure; Our review aims to summarize in an easy-to-follow flow recent relevant research evaluating the possible use and the clinical value of measuring CA 125 serum levels in acute HF.
methodsA thorough search in the main international databases identified a relevant pool of 170 articles, providing recently published data for this narrative review that used PRISMA guidelines.
resultsThere are data to sustain the role of carbohydrate antigen 125 (CA 125), a worldwide used marker of ovarian cancer, in patients with heart failure. Several studies have shown links between CA 125 levels and congestion seen in acute heart failure, high mortality and readmission rates at 6 months follow-up after discharge from acute heart failure and also a role of CA 125 in the guidance of heart failure therapy. There are also clinical trials that showed that several particularities of CA 125 make it even better than N-terminal pro b-type natriuretic peptide (NT-pro BNP)-a classical and more utilized marker of heart failure) in several scenarios of acute heart failure.
conclusionsAlthough the mechanism behind the upregulation of serum CA 125 in patients with congestive HF has not been confirmed nor fully understood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.